

PharmAust secures broad patent coverage for non-cancer applications

17 May 2017 – Perth, Australia: PharmAust (ASX: PAA), a clinical-stage oncology company, is pleased to announce the grant of a new patent in Australia covering the use of its lead drug for non-cancer applications, including neurodegenerative diseases, diabetes and age-related disorders.

The patent (AU 2013302209), entitled “**Compounds For The Treatment Of mTOR Pathway Related Diseases**”, relates to the use of aminoacetonitrile derivatives (AADs) for the treatment of mTOR pathway-related diseases and provides the company with protection for this IP until 2033.

‘Aminoacetonitrile derivatives’ include the Novartis Animal Health compound, Monepantel (MPL) the use of which PharmAust has patented for various disease indications and which is currently being evaluated in clinical trials for cancer by PharmAust.

Dr Richard Hopkins, PharmAust’s CEO commented “We are delighted with this grant of the “Method of Use” patent. In addition to our already granted patents covering the use of AADs to treat cancer, PharmAust has now secured a strong IP position for these compounds for treatment of non-cancer indications such as neurodegenerative diseases, diabetes and age-related disorders. There is increasing evidence that the mTOR pathway plays a major role in these diseases.

The key message is this patent expands the range of therapeutic indications we can target, enabling the company to explore new commercial opportunities in major markets”.

Enquiries:

Dr Richard Hopkins
CEO
Tel: 0405 656 868
rhopkins@pharmaust.com

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
raston@pharmaust.com

About PharmAust (PAA):

PAA is a clinical-stage company developing targeted cancer therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA’s subsidiary, Epichem, a highly successful contract synthetic drug manufacturer which is forecast to generate Aus\$3m in revenues in 2017 at a CAGR of 28%.

PAA’s lead drug candidate is Monopantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway - a key driver of cancer. MPL has been evaluated in Phase 1 clinical trials in humans and dogs. MPL treatment was well-tolerated and produced a significant reduction in key prognostic biomarkers. Further, 50% of end-stage Individuals achieved stable disease at low therapeutic doses providing support for MPL efficacy observed in preclinical studies.



PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as it advances the drug into Phase 2 clinical trial.

About NewSouth Innovations (NSI): NSI are a commercialisation company responsible for the protection and management of Intellectual Property (IP) developed at the University of New South Wales (UNSW). PharmAust acknowledges that the IP referred to in this announcement was assigned to Pitney Pharmaceuticals, a subsidiary of PharmAust, from the University of New South Wales in 2013

For personal use only